Efficacy of Ustekinumab Followed by Abatacept for the Treatment of Psoriasis Vulgaris
Status:
Completed
Trial end date:
2018-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if the use of ustekinumab, followed by abatacept,
will prevent relapse in people with moderate to severe plaque psoriasis.
Phase:
Phase 2
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)